Evidence of Springwater Acidification in the Vosges Mountains (North-East of France): Influence of Bedrock Buffering Capacity

Investigations on springwater acidity were carried out in the Vosges mountains (north-eastern France). Acid or poorly buffered spring and streamwaters were detected in the same area. The proportion of acid springwaters (pH < 5.6) is about 20% among 220 springs. The springwater pH on granite are equally spread between 5.0 and 6.8 whereas on sandstone a majority of springs is in the range 5.6 to 6.2. As a whole, but mainly on sandstone, from the 1960's to 1990's, the shape of the pH distributions shifts toward greater acidity. In the sandstone area, trends in pH, alkalinity, total hardness (corresponding to divalent cations), sulfate and nitrate were considered over the 30 yr period (1963-1996) in relation to the bedrock chemical composition. Kendall seasonal tau coefficients indicate that decreasing trends were significant for the first three parameters. Linear regression on the smoothed mean value revealed 18 and 90% decrease for pH and alkalinity respectively, for springwaters draining poor-base cation sandstone whereas only 8 and 30% decrease respectively, was observed on clay-enriched sandstone. On silica-enriched sandstone, alkalinity began to decrease in the early 70's as well as pH. Loss of alkalinity only occurred in the early 80's for springs draining clay enriched sandstone. This can be interpreted as a titration process by acid atmospheric inputs of the buffering capacity of weathering and exchange processes in the soils and the catchment bedrock. The nitrate presents an increasing step in the early seventies but possibly as a result of change in analytical technics and/or increase in atmospheric inputs mainly resulting from increase in fertiliser inputs in agricultural areas or in car traffic. Surprisingly no change in sulfate was noticed in any groups of springs probably as a result of the adsorption/mobilisation in the soils. These long-term trends in spring waters (1963-1996) confirmed the soil and streamwater acidification trends already mentioned in this region, in relation to acid atmospheric inputs since no climate nor forestry practice changes have been detected over the period. Moreover, in spite of acid atmospheric input reductions, no recovery can presently be detected

Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine

Treatment choice according to the individual conditions remains challenging, particularly in older patients with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS). The impact of performance status, comorbidities, and physical functioning on survival is not well defined for patients treated with hypomethylating agents. Here we describe the impact of performance status (14% ECOG performance status 2), comorbidity (40% HCT-comorbidity index ≥ 2), and physical functioning (41% short physical performance battery &lt; 9 and 17% ADL index &lt; 6) on overall survival (OS) in 115 older patients (age ≥ 66 years) treated on a clinical trial with a 10-day decitabine schedule. None of the patient-related variables showed a significant association with OS. Multivariable analysis revealed that age &gt; 76 years was significantly associated with reduced OS (HR 1.58; p = 0.043) and female sex was associated with superior OS (HR 0.62; p = 0.06). We further compared the genetic profiles of these subgroups. This revealed comparable mutational profiles in patients younger and older than 76 years, but, interestingly, revealed significantly more prevalent mutated ASXL1, STAG2, and U2AF1 in male compared to female patients. In this cohort of older patients treated with decitabine age and sex, but not comorbidities, physical functioning or cytogenetic risk were associated with overall survival.</p

Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine

Treatment choice according to the individual conditions remains challenging, particularly in older patients with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS). The impact of performance status, comorbidities, and physical functioning on survival is not well defined for patients treated with hypomethylating agents. Here we describe the impact of performance status (14% ECOG performance status 2), comorbidity (40% HCT-comorbidity index ≥ 2), and physical functioning (41% short physical performance battery &lt; 9 and 17% ADL index &lt; 6) on overall survival (OS) in 115 older patients (age ≥ 66 years) treated on a clinical trial with a 10-day decitabine schedule. None of the patient-related variables showed a significant association with OS. Multivariable analysis revealed that age &gt; 76 years was significantly associated with reduced OS (HR 1.58; p = 0.043) and female sex was associated with superior OS (HR 0.62; p = 0.06). We further compared the genetic profiles of these subgroups. This revealed comparable mutational profiles in patients younger and older than 76 years, but, interestingly, revealed significantly more prevalent mutated ASXL1, STAG2, and U2AF1 in male compared to female patients. In this cohort of older patients treated with decitabine age and sex, but not comorbidities, physical functioning or cytogenetic risk were associated with overall survival.</p

Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine

Treatment choice according to the individual conditions remains challenging, particularly in older patients with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS). The impact of performance status, comorbidities, and physical functioning on survival is not well defined for patients treated with hypomethylating agents. Here we describe the impact of performance status (14% ECOG performance status 2), comorbidity (40% HCT-comorbidity index ≥ 2), and physical functioning (41% short physical performance battery &lt; 9 and 17% ADL index &lt; 6) on overall survival (OS) in 115 older patients (age ≥ 66 years) treated on a clinical trial with a 10-day decitabine schedule. None of the patient-related variables showed a significant association with OS. Multivariable analysis revealed that age &gt; 76 years was significantly associated with reduced OS (HR 1.58; p = 0.043) and female sex was associated with superior OS (HR 0.62; p = 0.06). We further compared the genetic profiles of these subgroups. This revealed comparable mutational profiles in patients younger and older than 76 years, but, interestingly, revealed significantly more prevalent mutated ASXL1, STAG2, and U2AF1 in male compared to female patients. In this cohort of older patients treated with decitabine age and sex, but not comorbidities, physical functioning or cytogenetic risk were associated with overall survival.</p

Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine

Treatment choice according to the individual conditions remains challenging, particularly in older patients with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS). The impact of performance status, comorbidities, and physical functioning on survival is not well defined for patients treated with hypomethylating agents. Here we describe the impact of performance status (14% ECOG performance status 2), comorbidity (40% HCT-comorbidity index ≥ 2), and physical functioning (41% short physical performance battery &lt; 9 and 17% ADL index &lt; 6) on overall survival (OS) in 115 older patients (age ≥ 66 years) treated on a clinical trial with a 10-day decitabine schedule. None of the patient-related variables showed a significant association with OS. Multivariable analysis revealed that age &gt; 76 years was significantly associated with reduced OS (HR 1.58; p = 0.043) and female sex was associated with superior OS (HR 0.62; p = 0.06). We further compared the genetic profiles of these subgroups. This revealed comparable mutational profiles in patients younger and older than 76 years, but, interestingly, revealed significantly more prevalent mutated ASXL1, STAG2, and U2AF1 in male compared to female patients. In this cohort of older patients treated with decitabine age and sex, but not comorbidities, physical functioning or cytogenetic risk were associated with overall survival.</p

Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine

Treatment choice according to the individual conditions remains challenging, particularly in older patients with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS). The impact of performance status, comorbidities, and physical functioning on survival is not well defined for patients treated with hypomethylating agents. Here we describe the impact of performance status (14% ECOG performance status 2), comorbidity (40% HCT-comorbidity index ≥ 2), and physical functioning (41% short physical performance battery &lt; 9 and 17% ADL index &lt; 6) on overall survival (OS) in 115 older patients (age ≥ 66 years) treated on a clinical trial with a 10-day decitabine schedule. None of the patient-related variables showed a significant association with OS. Multivariable analysis revealed that age &gt; 76 years was significantly associated with reduced OS (HR 1.58; p = 0.043) and female sex was associated with superior OS (HR 0.62; p = 0.06). We further compared the genetic profiles of these subgroups. This revealed comparable mutational profiles in patients younger and older than 76 years, but, interestingly, revealed significantly more prevalent mutated ASXL1, STAG2, and U2AF1 in male compared to female patients. In this cohort of older patients treated with decitabine age and sex, but not comorbidities, physical functioning or cytogenetic risk were associated with overall survival.</p

Influence of granite mineralogy, rainfall, vegetation and relief on stream water chemistry (Vosges Mountains, north-eastern France)

International audienceThe influence of rock mineralogy, climate, vegetation and relief on stream water composition and export as a result of weathering is a major scientific concern both at the local scale, because of the link between stream chemistry and biodiversity, and at the global scale, in relation to global climate changes. Environmental factors influencing stream chemistry at baseflow were studied for 95 forested catchments located in the granite part of the Vosges Mountains (NE France). Mean annual rainfall, slope, altitude, catchment area, forest cover and granite composition were attributed to each catchment using a geographic information system (GIS) and spatially distributed databases. These variables were then used to model stream water concentrations in SO4, Ca, Mg, K, Na, Si, ANC (Acid Neutralizing Capacity) and pH via linear regression analyses. Sulfate concentration is mainly negatively correlated to the mean altitude of the catchment. Silica and Na concentrations are strongly correlated and negatively related to the mean annual rainfall and not to altitude. pH is positively related to the sum of Ca, Mg and K, but not to SO4. For any type of granite, Ca, Mg and pH are generally negatively related to the mean annual rainfall, and positively related to the catchment area. Calcium is best explained by the rock content in hornblende, Mg by the rock contents of biotite and hornblende, K by the content in K-feldspar. Nevertheless models differ for each granite type, in relation to the availability of weatherable minerals and, probably, to water pathways. This study shows the interest of spatial analysis methods for understanding stream water concentrations at the mountain range scale in combination with local process studies and modelling at the catchment scale

Notice explicative de la feuille Palluau à 1/50 000

Notizia esplicativa del foglio 535 Palluau della Carta Geologica Nazionale 1/50 000 della Franci

Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine.

Treatment choice according to the individual conditions remains challenging, particularly in older patients with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS). The impact of performance status, comorbidities, and physical functioning on survival is not well defined for patients treated with hypomethylating agents. Here we describe the impact of performance status (14% ECOG performance status 2), comorbidity (40% HCT-comorbidity index ≥ 2), and physical functioning (41% short physical performance battery &lt; 9 and 17% ADL index &lt; 6) on overall survival (OS) in 115 older patients (age ≥ 66 years) treated on a clinical trial with a 10-day decitabine schedule. None of the patient-related variables showed a significant association with OS. Multivariable analysis revealed that age &gt; 76 years was significantly associated with reduced OS (HR 1.58; p = 0.043) and female sex was associated with superior OS (HR 0.62; p = 0.06). We further compared the genetic profiles of these subgroups. This revealed comparable mutational profiles in patients younger and older than 76 years, but, interestingly, revealed significantly more prevalent mutated ASXL1, STAG2, and U2AF1 in male compared to female patients. In this cohort of older patients treated with decitabine age and sex, but not comorbidities, physical functioning or cytogenetic risk were associated with overall survival